The significant clinical success in the GLOW2 study and the accelerated BLA timeline are major value drivers that overshadow the modest EPS miss. The strengthened cash position supports the company's ambitious development plans. Traders should focus on upcoming catalysts: topline data from the DAYBREAK study (wet AMD) expected in Q3 2026 and from the PEAK study (MESI) in Q4 2026.
KOD drugs
KOD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 1 $42.81entry
- T+1 · 8mo ago −5.09%α −5.17% · $40.63
- T+5 · 7mo ago −1.05%α −4.82% · $42.36
- T+20 · 7mo ago +2.01%α −7.71% · $43.67
- T+60 · 5mo ago −11.84%α −25.22% · $37.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kodiak Sciences reported Q4 2025 net loss of $56.7M ($1.04/share), missing consensus by $0.03, driven by increased R&D spend. The filing was dominated by positive clinical news: strong Phase 3 GLOW2 topline results for Zenkuda (tarcocimab) in diabetic retinopathy, showing 62.5% of patients achieved ≥2-step improvement in DRSS vs. 3.3% for sham (p<0.0001), with an 85% risk reduction in sight-threatening complications. The company announced an accelerated path toward a multi-indication BLA submission and ended the year with $209.9M in cash after a $173M equity raise.
Key Financial Metrics
Key Facts
- Positive Phase 3 GLOW2 topline results for Zenkuda in diabetic retinopathy: 62.5% of patients achieved ≥2-step improvement in DRSS vs. 3.3% for sham (p<0.0001).
- 85% risk reduction in sight-threatening complications with Zenkuda vs. sham (2.4% vs. 15.8%, p=0.0001).
- Company announced an accelerated timeline for a multi-indication Biologics License Application (BLA) submission for Zenkuda.
- Completed a $173M follow-on equity offering in December 2025, ending the year with $209.9M in cash, up from $72.0M in Q3.
- Q4 2025 net loss was $56.7M ($1.04/share), missing consensus of $-1.01/share, due to higher R&D expenses of $45.5M (up from $31.8M YoY).
Financial Impact
Net loss of $56.7M ($1.04/share) for Q4 2025, missing consensus by $0.03. R&D expenses increased 43% YoY to $45.5M. Cash position improved to $209.9M after a $173M equity raise.
Risk Factors
- The stock has a high short interest, and future dilution is possible as the company will likely need to raise more capital to fund late-stage trials and a potential commercial launch.
- The upcoming DAYBREAK study in wet AMD is a critical hurdle; failure to meet its primary endpoint could significantly impact the stock despite the GLOW2 success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-134854 |
| Document: kod-20260331.htm | 0001193125-26-134854 |
| Document: 0001193125-26-134854-index-headers.html | 0001193125-26-134854 |
| Document: 0001193125-26-134854-index.html | 0001193125-26-134854 |
| Document: 0001193125-26-134854.txt | 0001193125-26-134854 |
| 8-K Data (Synthetic) | 0001193125-26-134854 |
Track record
13 reports on KOD
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $111.19 −5.97% settles Dec 15
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $111.19 −1.54% settles Dec 15
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $111.19 Now $111.19 +0.00% settles Dec 14
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $111.19 +3.82% settles Dec 8
- Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $111.19 −26.76% settles Nov 18
- Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $111.19 +12.93% ▲ +1.97% +1.27% vs SPY
- Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $111.19 +12.93% ▲ +1.97% +1.27% vs SPY
- Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $111.19 +23.65% ▼ −0.36% −0.32% vs SPY
- Aug 13, 202613w ago 8-K Neutral 4/10 No price data
- Aug 13, 202613w ago Press Release Neutral 6/10 Entry $41.35 to $33.14 Now $111.19 +168.90% ▼ −19.85% −17.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers